Aktive Positionen von Evy Lundgren-Åkerlund
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| XINTELA AB | Verwaltungsdirektor | - | - |
| Vorstandsvorsitzender | 01.04.2009 | - | |
| Gründer | 01.01.2009 | - | |
| Investor Relations Kontakt | - | - | |
Targinta AB
 Targinta AB BiotechnologyHealth Technology Part of Xintela AB, Targinta AB develops targeting and toxin-armed antibodies for cancer. The company is based in Lund, Sweden. Peter Ekolind has been the CEO of the Swedish company since 2022. | Direktor/Vorstandsmitglied | - | - |
Karriereverlauf von Evy Lundgren-Åkerlund
Ehemalige bekannte Positionen von Evy Lundgren-Åkerlund
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| Lund Life Science Incubator | Vorstandsvorsitzender | 01.01.2008 | 01.01.2012 |
| Geschäftsführer | 01.01.2008 | 01.01.2012 | |
Cartela AB
 Cartela AB Pharmaceuticals: MajorHealth Technology Cartela AB develops therapies for arthritic diseases. It products are mainly used by osteoarthritis and rheumatoid arthritis. Its business is based on the cell surface molecules, integrants a10ß1 and a11ß1. The company was founded by Evy Lundgren-Åkerlund and Donald Gullberg in 2000 and is headquartered in Lund, Sweden. | Technik-/Wissenschafts-/F&E-Leiter | 01.09.2000 | 24.12.2008 |
| Gründer | 01.09.2000 | 24.12.2008 |
Statistik
International
| Schweden | 5 |
Operativ
| Founder | 2 |
| Chief Executive Officer | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
Sektoral
| Health Technology | 4 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| XINTELA AB | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Cartela AB
Cartela AB Pharmaceuticals: MajorHealth Technology Cartela AB develops therapies for arthritic diseases. It products are mainly used by osteoarthritis and rheumatoid arthritis. Its business is based on the cell surface molecules, integrants a10ß1 and a11ß1. The company was founded by Evy Lundgren-Åkerlund and Donald Gullberg in 2000 and is headquartered in Lund, Sweden. | Health Technology |
| Lund Life Science Incubator | |
Targinta AB
Targinta AB BiotechnologyHealth Technology Part of Xintela AB, Targinta AB develops targeting and toxin-armed antibodies for cancer. The company is based in Lund, Sweden. Peter Ekolind has been the CEO of the Swedish company since 2022. | Health Technology |
- Börse
- Insiders
- Evy Lundgren-Åkerlund
- Erfahrung